KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Shares Outstanding (Diluted Average) (2016 - 2025)

AbbVie (ABBV) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) changed 0.0% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, changed 0.0% year-over-year, with the annual reading at $1.8 billion for FY2025, 0.0% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $1.8 billion at AbbVie, roughly flat from $1.8 billion in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $1.8 billion in Q1 2022, with the low at $1.8 billion in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 19.61% in 2021, then decreased 0.34% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $1.8 billion in 2021, then increased by 0.06% to $1.8 billion in 2022, then decreased by 0.28% to $1.8 billion in 2023, then changed by 0.0% to $1.8 billion in 2024, then changed by 0.0% to $1.8 billion in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $1.8 billion, $1.8 billion, and $1.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.